Your account is not claimed yet. You can sign up with ORCID to claim your account.

Gerald J Dal Pan (Gerald Dal Pan)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Venues

Drug safety

Clinical pharmacology and therapeutics

JMIR public health and surveillance

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Judith C Maro, Michael D Nguyen, Joy Kolonoski, Ryan Schoeplein, Ting-Ying Huang, Sarah K Dutcher, Gerald J Dal Pan, Robert Ball
Six Years of FDA's Postmarket Active Risk Identification and Analysis System (ARIA) in the Sentinel Initiative: Implications for Real World Evidence Generation. Clinical pharmacology and therapeutics (2023)
Mohamed Mohamoud, Carmen Cheng, Debra Ryan, Ivone Kim, Eileen Wu, Monica Muñoz, Cindy Kortepeter, Ellen Pinnow, Gerald J Dal Pan
Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019. Clinical pharmacology and therapeutics (2023)
Ida-Lina Diak, Kimberley Swank, Kate McCartan, Maya Beganovic, James Kidd, Neha Gada, Rachna Kapoor, Lisa Wolf, Laura Kangas, Jo Wyeth, Toni Salvatore, Melina Fanari, Andrew A LeBoeuf, Poonam Mishra, Michael D Blum, Gerald J Dal Pan
The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic. Drug safety (2022)
Esther H Zhou, Zhou Feng, Ellen Pinnow, Joann Lee, Daniel Bak, Travis Ready, Gerald J Dal Pan
Trend changes of national zolpidem users and exposure cases after FDA drug safety communications. Pharmacoepidemiology and drug safety 30 (11) (2021)
Kathryn Marwitz, S Christopher Jones, Cindy M Kortepeter, Gerald J Dal Pan, Monica A Muñoz
An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System. Drug safety 43 (5) (2021)
Monica A Muñoz, Gerald J Dal Pan, Yu-Jung Jenny Wei, Chris Delcher, Hong Xiao, Cindy M Kortepeter, Almut G Winterstein
Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. Drug safety 43 (4) (2021)
Monica A Muñoz, Gerald J Dal Pan
The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System. Drug safety 42 (10) (2020)
Michael S Sinha, Clark C Freifeld, John S Brownstein, Macarius M Donneyong, Paula Rausch, Brian M Lappin, Esther H Zhou, Gerald J Dal Pan, Ajinkya M Pawar, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR public health and surveillance 4 (1) (2018)

Gerald J Dal Pan.css-eqlu8i{font-size:small;padding-left:4px;} (Gerald Dal Pan)

Publication Activity (10 Years)

Top Topics

Top Venues

Gerald J Dal Pan (Gerald Dal Pan)